ATTO

Attovia Therapeutics Inc

17.30

Nov 11 • 1:29 PM ET +0.66 (3.97%)

Healthcare Biotechnology USA Small NASD

Nov 09, 8:15 PMAttovia Therapeutics posts Q3 2026 EPS -$0.76 on zero revenue, misses EPS but beats revenue estimates, ends quarter with $395.9M in cash and marketable securities, runway into 2030

Peers: ALMS ANAB IMVT ACRS UPB SYRE ETRA KYMR ABVX PTGX

| Held by: VTI VXF SCHA VTWO SCHB VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	790.86M
Enterprise Value	398.76M
Income	-
Sales	-
Book/sh	8.71
Cash/sh	8.66
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 05, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.99
P/C	2.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	34.66
Current Ratio	34.66
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.52
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-54.13%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	-36.72% -

Insider Own	37.71%
Insider Trans	19.66%
Inst Own	16.20%
Inst Trans	12.85%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	15.27%
SMA50	-3.18%
SMA200	-7.26%
Trades

Shs Outstand	45.68M
Shs Float	28.44M
Short Float	5.58%
Short Ratio	4.56
Short Interest	1.59M
52W High	28.00 -38.21%
52W Low	12.94 33.70%
Volatility	10.96% 9.85%
ATR (14)	1.49
RSI (14)	59.46
Beta	-
Rel Volume	0.14
Avg Volume	348.31K
Volume	30,263

Perf Week	10.90%
Perf Month	17.53%
Perf Quarter	-9.80%
Perf Half Y	-
Perf YTD	-17.62%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	43.20
Prev Close	16.64
Price	17.30
Change %	3.97%

Consensus

Strong Buy

Avg. Price Target

$43.20

Implied Upside

+149.7%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 31, 2026	Initiated	RRBC Capital Mkts	Outperform	$45	+160.1%
Aug 31, 2026	Initiated	MMorgan Stanley	Overweight	$39	+125.4%
Aug 31, 2026	Initiated	LLeerink Partners	Outperform	$52	+200.6%
Aug 31, 2026	Initiated	CCitigroup	Buy	$30	+73.4%

Nov-09-26 04:05PM	Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-26 04:05PM	Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis (GlobeNewswire)
Oct-27-26 04:05PM	Attovia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +8.07% +5.33%
Sep-28-26 04:05PM	Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 (GlobeNewswire)
Sep-22-26 01:39PM	Was Moderna Stock's Cancer Vaccine Run Visible In Advance? (Trefis)
04:05PM	Loading…
Sep-03-26 04:05PM	Attovia Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.58%
Sep-02-26 04:05PM	Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly)
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis)
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis)
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -8.72%
Aug-06-26 04:05PM	Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.94%
05:57AM	Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq (PR Newswire)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Proposed Sale	21.00	105,807	2,221,947		Aug 28 05:50 PM
WALSH COLIN	Director	Aug 06 '26	Buy	17.00	500,000	8,500,000	3,020,632	Aug 13 09:52 PM
WALSH COLIN	Director	Aug 05 '26	Buy	21.00	85,000	1,785,000	85,000	Aug 13 09:52 PM
WALSH COLIN	Director	Aug 05 '26	Sale	21.28	105,807	2,251,658	0	Aug 13 09:52 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 06 '26	Buy	17.00	500,000	8,500,000	3,020,632	Aug 13 09:51 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Buy	21.00	85,000	1,785,000	85,000	Aug 13 09:51 PM
GOLDMAN SACHS GROUP INC	Former 10% Owner	Aug 05 '26	Sale	21.28	105,807	2,251,658	0	Aug 13 09:51 PM
venBio Global Strategic Fund I	10% Owner	Aug 06 '26	Buy	17.00	382,352	6,499,984	4,181,367	Aug 10 04:12 PM
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	400,000	6,800,000	1,182,854	Aug 07 09:47 PM
Redmile Group, LLC	10% Owner	Aug 06 '26	Buy	17.00	200,000	3,400,000	982,854	Aug 07 09:47 PM
Sanofi	10% Owner	Aug 06 '26	Buy	17.00	300,000	5,100,000	1,082,855	Aug 07 03:45 PM
Frazier Life Sciences XI, L.P.	10% Owner	Aug 06 '26	Buy	17.00	588,235	9,999,995	6,154,213	Aug 06 05:35 PM

Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.

M.S.Mr. Tao Fu M.B.A.

Chief Scientific OfficerDr. Petter Veiby Ph.D.

M.P.H.Dr. Hubert C. Chen M.D.

Chief Financial OfficerMr. Steven Chan CPA

Chief Technology OfficerDr. Hangjun Zhan Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ATTO

Attovia Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.